Clinical Trial

Impact of CES1 Genotype on Remimazolam

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated October 15, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Remimazolam is primarily metabolized via CES1, and other drugs that are commonly metabolized by CES1 are known to have their pharmacokinetics and clinical effects affected by genetic polymorphisms in CES1. The goal of this observational study is to investigate the impact of the CES1 genotype on the pharmacokinetics, safety, and efficacy of remimazolam in patients undergoing elective surgery.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-04-24; most recent amendment 2024-10-09.
Status change: Not Yet Recruiting → Recruiting 2023-09-11
Trial Details
NCT Number NCT05841667
Lead Sponsor Korea University Guro Hospital
Conditions Adult, Middle Aged, Elective Surgical Procedures
Enrollment 120 participants
Start Date 2023-09-06
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-10-15